Navigation Links
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Date:4/14/2008

gh pain who experienced between one and four episodes of breakthrough pain per day and who were already taking maintenance opioid therapy. An extension study has demonstrated safety and tolerability in 197 patients followed over a six-month period.

In September 2006, the fentanyl buccal tablet formulation was approved in the United States under the trade name FENTORA(R) (fentanyl buccal tablet) [C-II].

About Breakthrough Cancer Pain

An estimated 3 million new cases of cancer were diagnosed in Europe in 2006. In patients with cancer, chronic pain often has two components: persistent pain and breakthrough cancer pain. Breakthrough pain is an intense transient flare of pain that interrupts or "breaks through" their persistent pain. The onset of breakthrough cancer pain is often sudden, reaches peak intensity within three minutes, and lasts for a median duration of 30 minutes. Patients may have up to four episodes of breakthrough pain per day. Episodes may occur during a specific activity or incident or spontaneously with no apparent cause.

Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, TREANDA(R) (bendamustine hydrochloride), AMRIX(R) (cyclobenzaprine hydrochlori
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
5. Cephalon General Counsel John E. Osborn to Resign Position
6. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
7. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
8. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Submits Supplemental New Drug Application for FENTORA
11. Cephalon Announces Strong Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... LOUIS (PRWEB) , ... August 03, 2015 , ... Nine ... in Iowa, Illinois and Indiana. Hosted by the Soil Health Partnership , the ... create lasting environmental benefits while potentially increasing farm productivity and income. , Brent Bible ...
(Date:8/3/2015)... -- According to a new market report ... Asia to Witness Highest Growth by ... culture market was valued at US$ 586.1 Mn in 2014 ... 29.1% to account for US$ 2,717.6 Mn by 2020. ... 3D cell culture refers to a process ...
(Date:7/31/2015)... Texas (PRWEB) , ... July 31, 2015 , ... ... report, offering competitive market analysis and premium industry insights on the global resorcinol ... based on a collective study of vivid market scenarios and analysis of primary ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
Breaking Biology Technology:Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... YORK, Aug. 17, 2011 Hadasit Bio-Holdings, Ltd. - ... all based on intellectual property developed by the Hadassah ... its portfolio company Enlivex Therapeutics (92% owned by Hadasit ... four groups in its Phase I / II clinical ...
... UAE, August 17, 2011 Global pharmaceutical ... trials due to the increase in drug development costs ... The Middle East is forecasted to be one of ... on availability of the required infrastructure, access to necessary ...
... 17, 2011 PAREXEL International Corporation (NASDAQ: ... been named Company of the Year for the Pharmaceutical ... only global, all-encompassing business awards program honoring great performances ... its global client base increase the efficiency of clinical ...
Cached Biology Technology:Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 2Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 3Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 4Middle East to be the Future in Clincial Trials 2PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 2PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 3PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 5
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/23/2015)... 23, 2015 Research and Markets ( ... "Global Outlook of the Biometrics Industry 2015 ... The global biometrics market is likely to ... applications owing to the uptake of multiple technologies ... that enhances the growth of biometrics in existing ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... a scientific detective story that uncovers a previously ... class of air pollutants. Incardona of the ... scientists from the U.S. government, Canadian government and ... to Ocean Basins: Emerging Chemical Contaminants and Human ...
... Feb. 15 The U.S. Department of ... begun collecting additional,fingerprints from international visitors arriving ... part of the department,s upgrade from two-,to ... legitimate,travel by more accurately and efficiently establishing ...
... tuna nets are a heart-wrenching reminder of the impact ... as by-catch, this killing of non-target species is a ... possible solution, advanced by NSERC grantee Dr. Suzana Dragicevic ... digital maps and mathematical analysis to visualize and better ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at Orlando International Airport 2New tool for resolving fisheries conflicts 2
XPMC2H Immunogen: XPMC2H (NP_065118, 323 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
...
Biology Products: